triphosphoric acid has been researched along with Malignant Melanoma in 2 studies
triphosphoric acid: used as water softener, peptizing agent, emulsifier & dispersing agent; ingredient of cleansers; meat preservative; RN given refers to parent cpd; structure
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Augustyn, K | 1 |
| Joseph, J | 1 |
| Patel, AB | 1 |
| Razmandi, A | 1 |
| Ali, AN | 1 |
| Tawbi, HA | 1 |
| Helms, MW | 1 |
| Jahn-Hofmann, K | 1 |
| Gnerlich, F | 1 |
| Metz-Weidmann, C | 1 |
| Braun, M | 1 |
| Dietert, G | 1 |
| Scherer, P | 1 |
| Grandien, K | 1 |
| Theilhaber, J | 1 |
| Cao, H | 1 |
| Wagenaar, TR | 1 |
| Schnurr, MM | 1 |
| Endres, S | 1 |
| Wiederschain, D | 1 |
| Scheidler, S | 1 |
| Rothenfußer, S | 1 |
| Brunner, B | 1 |
| König, LM | 1 |
2 other studies available for triphosphoric acid and Malignant Melanoma
| Article | Year |
|---|---|
Treatment experience with encorafenib plus binimetinib for BRAF V600-mutant metastatic melanoma: management insights for clinical practice.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Melanoma; Mitogen-Activated Protein Kinase K | 2023 |
Utility of the RIG-I Agonist Triphosphate RNA for Melanoma Therapy.
Topics: Animals; Cell Line, Tumor; DEAD Box Protein 58; Humans; Melanoma; Mice; Polyphosphates; Receptors, I | 2019 |